AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27979755 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened (NNS) beverages
Number of subjects: 432
Study 27979755 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 432
Study 27979755 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS beverages
Number of subjects: 432
Study 27979755 — intervention group
Group type: COMPARATOR
Intervention: NNS beverages and water
Number of subjects: 432
Study 26076755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual Cognitive Behavioural Therapy (CCBT)
Number of subjects: 89
Study 26076755 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 89
Study 23138352 — intervention group
Group type: EXPERIMENTAL
Intervention: BP + PPI (sodium risedronate with sodium rabeprazole)
Number of subjects: 180
Study 23138352 — intervention group
Group type: COMPARATOR
Intervention: BP (sodium risedronate only)
Number of subjects: 180
Study 16855451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SERT)
Number of subjects: 109
Study 16855451 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (NTP)
Number of subjects: 109
Study 12908854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily and caffeine 100 mg three times daily
Number of subjects: 24
Study 12908854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily and caffeine 100 mg three times daily
Number of subjects: 24
Study 12908854 — intervention group
Group type: COMPARATOR
Intervention: Caffeine alone
Number of subjects: 24
Study 10472157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 25
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 50 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 50 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 100 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 100 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 50 mg and 100 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 50 mg and 100 mg
Number of subjects: 30
Study 12799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg and 100 mg
Number of subjects: 30
Study 1829465 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day acitretin
Number of subjects: 65
Study 1829465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 1829465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin therapy after placebo
Number of subjects: 65
Study 6307458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and splanchnic nerve blockade (Group E&S)
Number of subjects: 12
Study 6307458 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia alone (Group E)
Number of subjects: 12
Study 6307458 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Group G)
Number of subjects: 12
Study 31235487 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted polygenic risk score (PRS) for metabolically favorable adiposity
Number of subjects: 341872
Study 31235487 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-3 concentrations
Number of subjects: 341872
Study 28214615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care and follow-up program
Number of subjects: 90
Study 28214615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25243325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg od
Number of subjects: 509
Study 25243325 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg od
Number of subjects: 509
Study 25243325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TDF and ADV
Number of subjects: 509
Study 23588709 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mm ports (Group A)
Number of subjects: 80
Study 23588709 — intervention group
Group type: COMPARATOR
Intervention: 5-mm ports (Group B)
Number of subjects: 80
Study 21083860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metformin
Number of subjects: 100
Study 21083860 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 100
Study 20509323 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) in women
Number of subjects: 80
Study 20509323 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) in men
Number of subjects: 80
Study 20509323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity markers in women
Number of subjects: 80
Study 20509323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity markers in men
Number of subjects: 80
Study 16442114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with estradiol +/- medroxyprogesterone
Number of subjects: 83
Study 16442114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 16442114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 83
Study 14579993 — intervention group
Group type: EXPERIMENTAL
Intervention: High starting dose: 1 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Number of subjects: 29
Study 14579993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low starting dose: 0.25 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Number of subjects: 29
Study 14579993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 29
Study 11052582 — intervention group
Group type: EXPERIMENTAL
Intervention: NE‐1530 (n=254)
Number of subjects: 507
Study 11052582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=253)
Number of subjects: 507
Study 11052582 — intervention group
Group type: EXPERIMENTAL
Intervention: NE‐1530
Number of subjects: 507
Study 11052582 — intervention group
Group type: COMPARATOR
Intervention: NE‐1530 and Placebo
Number of subjects: 507
Study 8797622 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared ear thermometers
Number of subjects: 20
Study 8797622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature
Number of subjects: 20
Study 8797622 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery temperature
Number of subjects: 20
Study 1283931 — intervention group
Group type: EXPERIMENTAL
Intervention: Local, laparoscopic Prostaglandin‐injection
Number of subjects: 33
Study 6094995 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 6094995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30482661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-sparing tri-modality therapy (TMT)
Number of subjects: 67
Study 30482661 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy (RC)
Number of subjects: 67
Study 29505578 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD (Door-to-Door Delivery)
Number of subjects: 2035
Study 29505578 — intervention group
Group type: COMPARATOR
Intervention: FPD (Fixed-Point Delivery)
Number of subjects: 2035
Study 29505578 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT (Directly Observed Treatment)
Number of subjects: 2035
Study 29505578 — intervention group
Group type: EXPERIMENTAL
Intervention: NDOT (Non-Directly Observed Treatment)
Number of subjects: 2035
Study 25487682 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 39
Study 25487682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 24518370 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg or 1600 μg of salbutamol
Number of subjects: 32
Study 24518370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 μg of salbutamol
Number of subjects: 32
Study 24518370 — intervention group
Group type: COMPARATOR
Intervention: Control environment (35°C, 40% relative humidity) during exercise
Number of subjects: 32
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine + Artesunate
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine + Azithromycin
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine + Atovaquone-Proguanil
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine monotherapy
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine combinations
Number of subjects: 640
Study 22912697 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-Azithromycin
Number of subjects: 640
Study 20016461 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-0707 (GH-releasing hormone super-agonist)
Number of subjects: 19
Study 20016461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17401781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 12.3 mg/day)
Number of subjects: 0
Study 17401781 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean dose 5.2 mg/day)
Number of subjects: 0
Study 17401781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 17401781 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 16280435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified maize-meal porridge
Number of subjects: 361
Study 16280435 — intervention group
Group type: COMPARATOR
Intervention: Control (unfortified porridge)
Number of subjects: 361
Study 11849248 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide SR
Number of subjects: 20
Study 11849248 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide LAR
Number of subjects: 20
Study 11849248 — intervention group
Group type: COMPARATOR
Intervention: lanreotide SR and octreotide LAR
Number of subjects: 20
Study 10194151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support including CPAP education at home, a 3-night trial of CPAP in a sleep center, and additional home visits
Number of subjects: 80
Study 10194151 — intervention group
Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 80
Study 10194151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who initiated their own referrals
Number of subjects: 80
Study 7756097 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation (100 mg levodopa/25 mg genserazide)
Number of subjects: 12
Study 7756097 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) formulation (300 mg levodopa/75 mg benserazide)
Number of subjects: 12
Study 2272818 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Training (PRT)
Number of subjects: 202
Study 2272818 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 202
Study 7465474 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of glucose a day
Number of subjects: 0
Study 7465474 — intervention group
Group type: EXPERIMENTAL
Intervention: 129 g of glucose a day
Number of subjects: 0
Study 7465474 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 30644570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of mirabegron (50 mg) and solifenacin (5 mg)
Number of subjects: 1794
Study 30644570 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin monotherapy
Number of subjects: 1794
Study 30644570 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron monotherapy
Number of subjects: 1794
Study 27830922 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor treatment (group A)
Number of subjects: 67
Study 27830922 — intervention group
Group type: COMPARATOR
Intervention: Behavioral and educational counseling (group B)
Number of subjects: 67
Study 25965713 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured weight management
Number of subjects: 69
Study 25965713 — intervention group
Group type: COMPARATOR
Intervention: General lifestyle advice
Number of subjects: 69
Study 22921175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0
Study 22921175 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 0
Study 22921175 — intervention group
Group type: COMPARATOR
Intervention: No flow
Number of subjects: 0
Study 21205408 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and environmental intervention focusing on menu planning, food presentation, and motivational strategies.
Number of subjects: 2510
Study 21205408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2510
Study 19934710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 52
Study 16907972 — intervention group
Group type: EXPERIMENTAL
Intervention: NUDOV (interactive case simulation system)
Number of subjects: 116
Study 16907972 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 116
Study 15271731 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 microg diluted with 9 mL of normal saline 30 min before surgery and PCEA with morphine (0.1 mg/mL) and clonidine (1.5 microg/mL) in 0.2% ropivacaine 100 mL after surgery
Number of subjects: 40
Study 15271731 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 mL before surgery and PCEA with morphine and ropivacaine after surgery
Number of subjects: 40
Study 15271731 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 40
Study 15271731 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 40
Study 11563588 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 11563588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan with autologous stem cell transplantation
Number of subjects: 0
Study 11563588 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatment strategies (nonmyeloablative allogeneic transplantation, vaccination)
Number of subjects: 0
Study 9436891 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Living Will
Number of subjects: 101
Study 9436891 — intervention group
Group type: COMPARATOR
Intervention: Centre for Bioethics Living Will
Number of subjects: 101
Study 8513525 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (antiemetic, selective serotonin 5-HT3 receptor antagonist) administered via rapid intravenous infusion over two minutes.
Number of subjects: 0
Study 8513525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) administered via rapid intravenous infusion.
Number of subjects: 0
Study 14591143 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Suloctidil daily
Number of subjects: 30
Study 14591143 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg Suloctidil daily
Number of subjects: 30
Study 14591143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29370256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-instructions
Number of subjects: 50
Study 29370256 — intervention group
Group type: COMPARATOR
Intervention: Control-instructions
Number of subjects: 50
Study 27300278 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing HIT group (n = 23)
Number of subjects: 63
Study 27300278 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing HIT group (n = 20)
Number of subjects: 63
Study 27300278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed HIT group (n = 20)
Number of subjects: 63
Study 24738705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement vignette and self-report items measuring grief expectations
Number of subjects: 348
Study 24738705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement vignette and self-report items measuring social distance
Number of subjects: 348
Study 24738705 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of the bereaved and circumstances of death
Number of subjects: 348
Study 23429813 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence program intervention using a life-story approach
Number of subjects: 135
Study 23429813 — intervention group
Group type: COMPARATOR
Intervention: Active control group participating in casual discussions
Number of subjects: 135
Study 23429813 — intervention group
Group type: COMPARATOR
Intervention: Passive control group participating in casual discussions
Number of subjects: 135
Study 20810606 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meals composed of high-amylose barley kernels or high-β-glucan barley kernels
Number of subjects: 15
Study 20810606 — intervention group
Group type: COMPARATOR
Intervention: Evening meal with white wheat bread
Number of subjects: 15
Study 20810606 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast following evening test meals
Number of subjects: 15
Study 17688420 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-sodium diet (120 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Number of subjects: 232
Study 17688420 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (80 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Number of subjects: 232
Study 16182672 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (training course for parents)
Number of subjects: 51
Study 16182672 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to the course (control group)
Number of subjects: 51
Study 12462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stressor condition
Number of subjects: 0
Study 12462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stress condition
Number of subjects: 0
Study 12462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stress condition with elevated Beck Depression Inventory scores
Number of subjects: 0
Study 12462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated depression scores
Number of subjects: 0
Study 10350104 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (Group A)
Number of subjects: 43
Study 10350104 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (Group B)
Number of subjects: 43
Study 10350104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 1 (TnT peak < 1 ng/ml)
Number of subjects: 43
Study 10350104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 2 (TnT peak between 1 and 3 ng/ml)
Number of subjects: 43
Study 10350104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 3 (TnT peak > 3 ng/ml)
Number of subjects: 43
Study 7859141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 600 mg/day plus acyclovir (ACV) 4,800 mg orally per day
Number of subjects: 93
Study 7859141 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 600 mg/day plus placebo
Number of subjects: 93
Study 1838032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg once daily)
Number of subjects: 12
Study 1838032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7171073 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy (MMTP)
Number of subjects: 0
Study 7171073 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcoholics (AA)
Number of subjects: 0
Study 7171073 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive alcoholics (IA)
Number of subjects: 0
Study 7171073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholics (NA)
Number of subjects: 0
Study 6423586 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.4 mg/ml saline)
Number of subjects: 6
Study 6423586 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion 1 ml)
Number of subjects: 6
Study 6423586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infusion control)
Number of subjects: 6
Study 6423586 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials (naloxone, control, placebo)
Number of subjects: 6
Study 30155949 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interval (LI) group (surgery after 8 weeks)
Number of subjects: 327
Study 30155949 — intervention group
Group type: COMPARATOR
Intervention: Classical interval (CI) group (surgery within 8 weeks)
Number of subjects: 327
Study 30155949 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interval (LI) group
Number of subjects: 327
Study 30155949 — intervention group
Group type: COMPARATOR
Intervention: Classical interval (CI) group
Number of subjects: 327
Study 27143669 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization treatment with chlorhexidine bathing and nasal mupirocin
Number of subjects: 136
Study 24589827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at recruitment questionnaire (RQ)
Number of subjects: 48215
Study 24589827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at interview format (IF)
Number of subjects: 48215
Study 24589827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at both RQ and IF
Number of subjects: 48215
Study 22571408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg intravenously every 90 days
Number of subjects: 118
Study 22571408 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mg calcium with 400 iu vitamin D daily)
Number of subjects: 118
Study 20047702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention plus a health information leaflet
Number of subjects: 103
Study 20047702 — intervention group
Group type: COMPARATOR
Intervention: Health information leaflet alone
Number of subjects: 103
Study 20047702 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 103
Study 19140508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0
Study 19140508 — intervention group
Group type: COMPARATOR
Intervention: Actovegin
Number of subjects: 0
Study 15841664 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 0